Cadence Pharmaceuticals Announces FDA Concurrence With Clinical Development Plan For Acetavance(TM) Cadence Pharmaceuticals, Inc. (Nasdaq: CADX) announced that it has received written guidance from the U.S. Food and Drug Administration (FDA) that one post-operative pain trial (Sinatra Study) and one fever trial (Study 302) are sufficient to meet the pivotal clinical trial requirements for submission of a New Drug Application (NDA) for Acetavance, the company's intravenous formulation of acetaminophen for the treatment of acute pain and fever in adults and children.
Source: www.medicalnewstoday.comPhase II Data On Lilly's Antibody Show It Affects Amyloid Beta, A Protein Believed To Be Associated With Alzheimer's Disease Eli Lilly and Company (NYSE: LLY) announced interim results of its Phase II study of LY2062430, an investigational anti-amyloid beta monoclonal antibody for the treatment of mild to moderate Alzheimer's disease. In this study, intravenously administered LY2062430 bound to the amyloid beta protein, resulting in increased amounts of amyloid beta in participants' blood and cerebrospinal fluid.
Source: www.medicalnewstoday.comPeptimmune Announces Grant Of United States Patent For PI-2301 Peptide Copolymer For Multiple Sclerosis Peptimmune, Inc. a privately held biotechnology company, announced today the grant of US Patent Number 7,381,790 (the '790 patent) which protects the composition of matter for its PI-2301 peptide copolymer for the treatment of autoimmune diseases. PI-2301 is currently in a Phase Ib multiple-ascending dose, double-blind, placebo-controlled randomized study in subjects with multiple sclerosis.
Source: www.medicalnewstoday.comGSK - Changes To Medicines Distribution Arrangements, UK GSK UK has announced that from 1st November 2008 it will partner with two of its current logistics service providers, AAH Pharmaceuticals Ltd and UniChem Ltd, to deliver its
prescription medicines to customers in the UK. The NPA's Board will discuss this development at its meeting today. NPA chief executive, John Turk, said: "The NPA board will discuss urgently the implications of this new development for our members.
Source: www.medicalnewstoday.comDeCODE And SGENE Consortium Discover Deletions In The Human Genome Linked To Risk Of Schizophrenia In a major paper published in the online edition of the journal Nature, scientists from deCODE genetics (Nasdaq: DCGN) and the University of Iceland, along with academic colleagues from the deCODE-led European SGENE consortium, China and the United States, report the discovery of three rare deletions in the human genome that confer risk of schizophrenia.
Source: www.medicalnewstoday.comAnavex Presents Neuroprotective Effects Of Anavex 1-41 At The International Conference On Alzheimer's Disease 2008 ANAVEX Life Sciences Corp. (OTCBB: AVXL), a biopharmaceutical company engaged in the discovery and development of novel therapeutics to treat Central Nervous System (CNS) diseases and cancer, presented data from the company's novel compound, ANAVEX 1-41, targeting Alzheimer's disease, at the International Conference on Alzheimer's Disease (ICAD) 2008, Chicago, USA, July 26 to 31, 2008.
Source: www.medicalnewstoday.comNile Therapeutics Announces Dosing In Second Phase Ib Study Of CD-NP In Heart Failure Patients Nile Therapeutics, Inc. (Nasdaq: NLTX), announced that Mayo Clinic has initiated a Phase Ib, double-blind, placebo-controlled clinical study of CD-NP, a novel chimeric natriuretic peptide, in development for the treatment of acute decompensated heart failure. The primary objective of the study is to assess renal, neurohumoral and non-invasive hemodynamic physiologic parameters of intravenous infusions of CD-NP in patients with heart failure.
Source: www.medicalnewstoday.comCigna, Express Scripts Agree To Pay $27M To Settle New York State Drug Switching Case Cigna and Express Scripts have agreed to a $27 million settlement in a 2004 lawsuit by New York State accusing Express Scripts of persuading physicians to switch
prescriptions to
drugs for which larger rebates could be obtained from manufacturers without informing patients of the change, the
Source: www.medicalnewstoday.com
# posted by Network @ 1:00 PM
